May 9, 1977

Diethylstilbestrol: Recommended Dosages for Different Categories of Breast Cancer PatientsReport of the Cooperative Breast Cancer Group

Author Affiliations

From State University of New York, Downstate Medical Center, Brooklyn (Dr Carter); State University of New York at Buffalo (Dr Sedransk); Harvard Medical School, Pondville Hospital, Walpole, Mass (Dr Kelley); University of Wisconsin Medical Center, Madison (Dr Ansfield); University of Pennsylvania School of Medicine, Philadelphia (Dr Ravdin); Henry Ford Hospital, Detroit (Dr Talley); and the Clinical Trials Research Center, Louisiana State University Medical Center, New Orleans (Dr Potter).

JAMA. 1977;237(19):2079-2085. doi:10.1001/jama.1977.03270460065023

A total of 523 postmenopausal breast cancer patients with progressive disease were entered in a randomized, double-blind study of four dosages of diethylstilbestrol (DES): 1.5,15,150, or 1,500 mg/day. Higher dosages produced significantly (P <.05) higher regression rates: 21% for the 1,500 mg dosage, 17% for the 150 mg dosage, 15% for the 15 mg dosage, and 10% for 1.5 mg dosage. Durations of regressions were similar regardless of the dosages used to induce them. Although the highest dosage produced the highest regression rate overall, selecting the best dosage or treatment of choice for each type of patient based on menopausal age and on dominant metastatic site would result in more regressions.

(JAMA 237:2079-2085, 1977)